Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change $ Change
grade B $39.56 1.07% 0.42
ACAD closed up 1.07 percent on Thursday, February 23, 2017, on 89 percent of normal volume.

Earnings due: Feb 28

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Feb 21 Spinning Top Other 0.92%
Feb 17 NR7 Range Contraction 0.71%
Feb 17 Narrow Range Bar Range Contraction 0.71%
Feb 17 Golden Cross Bullish 0.71%
Feb 17 Slingshot Bullish Bullish Swing Setup 0.71%
Feb 15 1,2,3 Pullback Bullish Bullish Swing Setup 0.23%
Feb 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.23%
Feb 15 Jack-in-the-Box Bullish Bullish Swing Setup 0.23%
Feb 14 Wide Range Bar Range Expansion -0.33%
Feb 14 1,2,3 Pullback Bullish Bullish Swing Setup -0.33%

Older signals for ACAD ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer’s disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 42.49
52 Week Low 17.02
Average Volume 2,608,342
200-Day Moving Average 31.81
50-Day Moving Average 32.41
20-Day Moving Average 36.96
10-Day Moving Average 38.78
Average True Range 1.52
ADX 41.31
+DI 36.17
-DI: 8.94
Chandelier Exit (Long, 3 ATRs) 36.27
Chandelier Exit (Short, 3 ATRs) 33.68
Upper Bollinger Band 42.2
Lower Bollinger Band 31.72
Percent B (%b) 0.75
Bandwidth 0.28355